[1] Bradley, J.D., Moughan, J., Graham, M.V., et al. (2010) A Phase I/II Radiation Dose Escalation Study with Concurrent Chemotherapy for Patients with Inoperable Stages I to III Non-Small-Cell Lung Cancer: Phase I Results of RTOG 0117. International Journal of Radiation Oncology, Biology, Physics, 77, 367-372.
http://dx.doi.org/10.1016/j.ijrobp.2009.04.029
[2] Bradley, J. (2005) A Review of Radiation Dose Escalation Trials for Non-Small Cell Lung Cancer within the Radiation Therapy Oncology Group. Seminars in Oncology, 32, 111-113.
http://dx.doi.org/10.1053/j.seminoncol.2005.03.020
[3] Bradley, J.D., Paulus, R., Komaki, R., et al. (2013) A Randomized Phase III Comparison of Standard-Dose (60 Gy) versus High-Dose (74 Gy) Conformal Chemoradiotherapy with or without Cetuximab for Stage III Non-Small Cell Lung Cancer: Results on Radiation Dose in RTOG 0617. ASCO Meeting Abstracts, 31, 7501.
[4] Chi, A., Nguyen, N.P., Welsh, J.S., et al. (2014) Strategies of Dose Escalation in the Treatment of Locally Advanced Non-Small Cell Lung Cancer: Image Guidance and beyond. Frontiers in Oncology, 4, 156.
http://dx.doi.org/10.3389/fonc.2014.00156
[5] Cox, J.D. (2012) Are the Results of RTOG 0617 Mysterious? International Journal of Radiation Oncology, Biology, Physics, 82, 1042-1044.
http://dx.doi.org/10.1016/j.ijrobp.2011.12.032
[6] Guckenberger, P.D.M., Kavanagh, A. and Partridge, M. (2012) Combining Advanced Radiotherapy Technologies to Maximize Safety and Tumor Control Probability in Stage III Non-Small Cell Lung Cancer. Strahlentherapie und Onkologie, 188, 894-900.
http://dx.doi.org/10.1007/s00066-012-0161-9
[7] Harada, H., Nishio, M., Murakami, H., et al. (2013) Dose-Escalation Study of Three-Dimensional Conformal Thoracic Radiotherapy with Concurrent S-1 and Cisplatin for Inoperable Stage III Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 14, 440-445.
http://dx.doi.org/10.1016/j.cllc.2013.01.003
[8] Howlader, N., Noone, A.M., Krapcho, M., et al. (2014) SEER Cancer Statistics Review, 1975-2011. National Cancer Institute, Bethesda.
http://seer.cancer.gov/csr/1975_2011/
[9] Kong, F.M., Hayman, J.A. and Griffith, K.A. (2006) Final Toxicity Results of a Radiation-Dose Escalation Study in Patients with Non-Small-Cell Lung Cancer (NSCLC): Predictors for Radiation Pneumonitis and Fibrosis. International Journal of Radiation Oncology, Biology, Physics, 65, 1075-1086.
http://dx.doi.org/10.1016/j.ijrobp.2006.01.051
[10] Liao, Z.X., Komaki, R.R., Thames Jr., H.D., et al. (2010) Influence of Technologic Advances on Outcomes in Patients with Unresectable, Locally Advanced Non-Small-Cell Lung Cancer Receiving Concomitant Chemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics, 76, 775-781.
http://dx.doi.org/10.1016/j.ijrobp.2009.02.032
[11] Partridge, M., Ramos, M., Sardaro, A. and Brada, M. (2011) Dose Escalation for Non-Small Cell Lung Cancer: Analysis and Modelling of Published Literature. Radiotherapy and Oncology, 99, 6-11.
http://dx.doi.org/10.1016/j.radonc.2011.02.014
[12] Philipp, J. and Baumann, M. (2014) Caution with Hypofractionated Dose-Escalating Radiotherapy in Non-Small Cell Lung Cancer. Strahlentherapie und Onkologie, 190, 597-599.
http://dx.doi.org/10.1007/s00066-014-0667-4
[13] Rosenman, J.G., Halle, J.S., Socinski, M.A., et al. (2002) High-Dose Conformal Radiotherapy for Treatment of Stage IIIA/IIIB Non-Small-Cell Lung Cancer: Technical Issues and Results of a Phase I/II Trial. International Journal of Radiation Oncology, Biology, Physics, 54, 348-356.
http://dx.doi.org/10.1016/S0360-3016(02)02958-9
[14] Saunders, M., Royas, A., Lyn, E., et al. (1998) Experience with Dose Escalation Using CHARTWEL (Continuous Hyperfractionated Accelerated Radiotherapy Weekend Less) in Non-Small-Cell Lung Cancer. British Journal of Cancer, 78, 1323-1328.
http://dx.doi.org/10.1038/bjc.1998.678
[15] Saunders, M., Dische, S., Barrett, A., et al. (1997) Continuous Hyperfractionated Accelerated Radiotherapy (CHART) versus Conventional Radiotherapy in Non-Small-Cell Lung Cancer: A Randomised Multicentre Trial. The Lancet, 350, 161-165.
http://dx.doi.org/10.1016/S0140-6736(97)06305-8
[16] Schroder, C., Ivo, M. and Buchali, A. (2013) Does High-Dose Radiotherapy Benefit Palliative Lung Cancer Patients? Strahlentherapie und Onkologie, 189, 771-776.
http://dx.doi.org/10.1007/s00066-013-0360-z
[17] Socinski, M.A., Morris, D.E. and Halle, J.S. (2004) Induction and Concurrent Chemotherapy with High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non-Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial. Journal of Clinical Oncology, 22, 4341-4350.
http://dx.doi.org/10.1200/JCO.2004.03.022
[18] Terakedis, B. and Sause, W. (2011) Radiation Dose Escalation in Stage III Non-Small-Cell Lung Cancer. Frontiers in Oncology, 1, 47.
http://dx.doi.org/10.3389/fonc.2011.00047
[19] Wang, L., Correa, C.R., Zhao, L., et al. (2009) The Effect of Radiation Dose and Chemotherapy on Overall Survival in 237 Patients With Stage III Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 73, 1383-1390.
http://dx.doi.org/10.1016/j.ijrobp.2008.06.1935
[20] Wurstbauer, K., Deutschmann, H., Dagn, K., et al. (2013) DART-Bid (Dose-Differentiated Accelerated Radiation Therapy, 1.8 Gy Twice Daily)—A Novel Approach for Non-Resected NSCLC: Final Results of a Prospective Study, Correlating Radiation Dose to Tumor Volume. Radiation Oncology, 8, 49.
http://dx.doi.org/10.1186/1748-717X-8-49